Vegf inhibition, hypertension, and renal toxicity

Current Oncology Reports

Volumn 14, Issue 4, 2012, Pages 285-294

  Hayman, Suzanne R ^a   Leung, Nelson ^a   Grande, Joseph P ^a   Garovic, Vesna D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bevacizumab; Hypertension; Podocyturia; Proteinuria; Renal toxicity; Thrombotic microangiopathy; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; AXITINIB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CEDIRANIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; NEBIVOLOL; NEPHRIN; NIFEDIPINE; NITRIC OXIDE; PAMIDRONIC ACID; PAZOPANIB; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVERSE OUTCOME; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR RISK; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CARCINOMA; CONGESTIVE HEART FAILURE; CRYOGLOBULINEMIA; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; GASTROINTESTINAL STROMAL TUMOR; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; GLOMERULUS EPITHELIUM; GLOMERULUS FILTRATION; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; INHIBITION KINETICS; INTERSTITIAL NEPHRITIS; KIDNEY CARCINOMA; KIDNEY INJURY; KIDNEY METASTASIS; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MICROANGIOPATHY; MICROVASCULATURE; MOLECULAR MODEL; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOLOGICAL BLOCKING; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEINURIA; QUALITY OF LIFE; RETICULOENDOTHELIOSIS; RETINA MACULA DEGENERATION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; HYPERTENSION; PROTEIN KINASE INHIBITORS; PROTEINURIA; RENAL INSUFFICIENCY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865658329     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0242-z     Document Type: Article

References (82)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971;285:1182-6.
2. Eremina V, Quaggin SE. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol. 2010;30:582-90.
3. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer. 2006;42:3127-39. (Pubitemid 44869016)
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-76. (Pubitemid 36749215)
5. • Kappers MH, van Esch JH, Sleijfer S, Danser AH, van den Meiracker AH. Cardiovascular and renal toxicity during angiogenesis inhibition: Clinical and mechanistic aspects. J Hypertens. 2009;27:2297-309. Excellent overview of the vascular effects and toxicities of anti-VEGF agents.
6. Ebos JM, Bocci G, Man S, et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res. 2004;2:315-26. (Pubitemid 39025294)
7. Kitamoto Y, Tokunaga H, Miyamoto K, Tomita K. VEGF is an essential molecule for glomerular structuring. Nephrol Dial Transplant. 2002;17 Suppl 9:25-7.
8. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186-93. (Pubitemid 46178407)
9. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis. 2004;7:193-201.
10. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007;7:475-85. (Pubitemid 46809172)
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. (Pubitemid 38702844)
12. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-9. (Pubitemid 46224178)
13. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-34. (Pubitemid 36910021)
14. Mourad JJ, Levy BI. Mechanisms of antiangiogenic-induced arterial hypertension. Curr Hypertens Rep. 2011;13:289-93.
15. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465-77.
16. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:3045-54. (Pubitemid 47218051)
17. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27:3126-32.
18. Trotti A, Byhardt R, Stetz JA, et al. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13-47. (Pubitemid 30179675)
19. Agabiti-Rosei E. Structural and functional changes of the microcirculation in hypertension: Influence of pharmacological therapy. Drugs. 2003;63(Spec No 1):19-29. (Pubitemid 36384615)
20. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-81. (Pubitemid 36962641)
21. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-52. (Pubitemid 37553153)
22. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol. 2008;9:117-23.
23. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432-9.
24. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26:3709-14.
25. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596-604.
26. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274:H1054-8.
27. Horowitz JR, Rivard A, van der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxidedependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol. 1997;17:2793-800. (Pubitemid 28016023)
28. Zachary I. VEGF signalling: Integration and multi-tasking in endothelial cell biology. Biochem Soc Trans. 2003;31:1171-7. (Pubitemid 38030933)
29. Gelinas DS, Bernatchez PN, Rollin S, Bazan NG, Sirois MG. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: Role of PI3K, PKC and PLC pathways. Br J Pharmacol. 2002;137:1021-30 (Pubitemid 35440742)
30. Li B, Ogasawara AK, Yang R, et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension. 2002;39:1095-100. (Pubitemid 34620130)
31. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107:1359-65. (Pubitemid 36350732)
32. Zou AP, Cowley Jr AW. Role of nitric oxide in the control of renal function and salt sensitivity. Curr Hypertens Rep. 1999;1:178-86.
33. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19:927-34. (Pubitemid 351627309)
34. Feihl F, Liaudet L, Waeber B, Levy BI. Hypertension: A disease of the microcirculation? Hypertension. 2006;48:1012-7. (Pubitemid 44772698)
35. Kiefer FN, Misteli H, Kalak N, et al. Inhibition of NO biosynthesis, but not elevated blood pressure, reduces angiogenesis in rat models of secondary hypertension. Blood Press. 2002;11:116-24. (Pubitemid 34537522)
36. Steeghs N, Gelderblom H, Roodt JO, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14:3470-6.
37. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006;24:1363-9. (Pubitemid 46621999)
38. Mundel P, Kriz W. Cell culture of podocytes. Exp Nephrol. 1996;4:263-6. (Pubitemid 26342894)
39. Nagata M, Yamaguchi Y, Ito K. Loss of mitotic activity and the expression of vimentin in glomerular epithelial cells of developing human kidneys. Anat Embryol (Berl). 1993;187:275-9. (Pubitemid 23128035)
40. Reiser J, Kriz W, Kretzler M, Mundel P. The glomerular slit diaphragm is a modified adherens junction. J Am Soc Nephrol. 2000;11:1-8. (Pubitemid 30020420)
41. Kestila M, Lenkkeri U, Mannikko M, et al. Positionally cloned gene for a novel glomerular protein -nephrin -is mutated in congenital nephrotic syndrome. Mol Cell. 1998;1:575-82. (Pubitemid 128374693)
42. Donoviel DB, Freed DD, Vogel H, et al. Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell Biol. 2001;21:4829-36. (Pubitemid 32588261)
43. Schwarz K, Simons M, Reiser J, et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest. 2001;108:1621-9. (Pubitemid 33144872)
44. Shih NY, Li J, Karpitskii V, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science. 1999;286:312-5. (Pubitemid 29484698)
45. Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIVassociated nephropathy. J Am Soc Nephrol. 1999;10:51-61. (Pubitemid 29034942)
46. Garovic VD, Wagner SJ, Petrovic LM, et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant. 2007;22:1136-43. (Pubitemid 46523429)
47. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-36. (Pubitemid 351398487)
48. Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008;100:282-4. (Pubitemid 351480534)
49. Eskens FAP, van Doorn A. An open label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors (Abstract). J Clin Oncol. 2006;24:2034.
50. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer. 2010;46:439-48.
51. Nasr SH, Snyder RW, Bhagat G, Markowitz GS. Chronic lymphocytic leukemia and cryoglobulinemic glomerulonephritis. Kidney Int. 2007;71:93. (Pubitemid 46094679)
52. Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother. 2007;5:341-4.
53. Izzedine H, Brocheriou I, Rixe O, Deray G. Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant. 2007;22:2411. (Pubitemid 47244737)
54. Stokes MB, Erazo MC, D'Agati VD. Glomerular disease related to anti-VEGF therapy. Kidney Int. 2008;74:1487-91.
55. Stylianou K, Lioudaki E, Papadimitraki E, et al. Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. Nephrol Dial Transplant. 2011;26:1742-5.
56. Costero O, Picazo ML, Zamora P, et al. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant. 2010;25:1001-3.
57. Bollee G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009;24:682-5.
58. Izzedine H, Brocheriou I, Deray G, Rixe O. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant. 2007;22:1481-2.
59. Pelle G, Shweke N, Duong Van Huyen JP, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis. 2011;57:756-9.
60. Yu D, Petermann A, Kunter U, et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005;16:1733-41. (Pubitemid 41716479)
61. •• Müller-Deile J, Bröcker V, Grünwald V, et al. Renal side effects of VEGF-blocking therapy. NDT Plus. 2010;3:172-5. First article reporting the presence of podocyturia in patients with proteinuria treated with anti-VEGF therapy.
62. Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T. Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol. 2011.
63. •• Steeghs N, Rabelink TJ, op 't Roodt J, et al. Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol. 2010;21:1100-5. First study showing that decreased capillary density as a result of bevacizumab is reversible and that capillary density may represent a marker of treatment efficacy.
64. Ravaud A, Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol. 2009;20:966-7. author reply 7.
65. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol. 2007;18:1117. (Pubitemid 47050505)
66. Levy BI. Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor. Ann Oncol. 2009;20:200-3.
67. Bono P, Elfving H, Utriainen T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol. 2009;20:393-4.
68. Mir O, Ropert S, Alexandre J, Goldwasser F. Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol. 2009;20:967-70.
69. • Osterlund P, Soveri LM, Isoniemi H, et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer. 2011;104:599-604. Study that most clearly demonstrates an association between hypertension and overall survival in patients treated with bevacizumab.
70. Kim JJ, Vaziri SAJ, Rini BI, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer. 2012:118(7):1946-54.
71. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study. Lancet Oncol. 2011;12:1143-50.
72. Langenberg MH, van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: Results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol. 2009;27:6152-9.
73. Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K. Nifedipineinduced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/ NO pathway. Hypertens Res. 2005;28:147-53. (Pubitemid 40663066)
74. Molteni A, Heffelfinger S, Moulder JE, Uhal B, Castellani WJ. Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy. Anticancer Agents Med Chem. 2006;6:451-60. (Pubitemid 44377779)
75. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807-15.
76. Kelly DJ, Aaltonen P, Cox AJ, et al. Expression of the slitdiaphragm protein, nephrin, in experimental diabetic nephropathy: Differing effects of anti-proteinuric therapies. Nephrol Dial Transplant. 2002;17:1327-32. (Pubitemid 34812081)
77. Dirix LY, Maes H, Sweldens C. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors. Ann Oncol. 2007;18:1121-2. (Pubitemid 47050509)
78. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension. 2006;48:622-7. (Pubitemid 44843865)
79. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: The growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007;7:127-34.
80. Launay-Vacher V, Ayllon J, Janus N, et al. Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. Urol Oncol. 2011;29:492-4.
81. Gupta S, Parsa V, Heilbrun LK, et al. Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs. 2011;22:794-800.
82. Raina S, Honer M, Kramer SD, et al. Anti-VEGF antibody treatment accelerates polycystic kidney disease. Am J Physiol Renal Physiol. 2011;301:F773-83.